|Articles|September 1, 2019
- BioPharm International-09-01-2019
- Volume 32
- Issue 9
BioPharm International, September 2019 Issue (PDF)
Click the title above to open the BioPharm International September 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Improving Oligonucleotide Analysisover 6 years ago
Dealing with particulates or aggregates in biologicsover 6 years ago
Putting Biopharma Stability Testing Under the Microscopeover 6 years ago
What’s New in Manufacturing: Process Chromatographyover 6 years ago
More Predictable Post-Approval Change Policy on Horizonover 6 years ago
Best Practices for Studying Stability in Biologicsover 6 years ago
Developing an Effective Contamination Control Strategyover 6 years ago
Biologics Continue to Grow and Create Outsourcing Opportunitiesover 6 years ago
Plan Now to Share Your Expertise in 2020Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5
